Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.
Identifieur interne : 001119 ( PubMed/Corpus ); précédent : 001118; suivant : 001120Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.
Auteurs : William C. Weldon ; Maria P. Martin ; Vladimir Zarnitsyn ; Baozhong Wang ; Dimitrios Koutsonanos ; Ioanna Skountzou ; Mark R. Prausnitz ; Richard W. CompansSource :
- Clinical and vaccine immunology : CVI [ 1556-679X ] ; 2011.
English descriptors
- KwdEn :
- Animals, Disease Models, Animal, Hemagglutinin Glycoproteins, Influenza Virus (administration & dosage), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Immunity, Mucosal, Influenza A virus (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Injections, Intradermal (methods), Lung (virology), Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Survival Analysis, Th1 Cells (immunology), Vaccination (methods), Vaccines, Subunit (administration & dosage), Vaccines, Subunit (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Load.
- MESH :
- chemical , administration & dosage : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Vaccines, Subunit, Vaccines, Synthetic.
- chemical , immunology : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Vaccines, Subunit, Vaccines, Synthetic.
- immunology : Influenza A virus, Orthomyxoviridae Infections, Th1 Cells.
- methods : Injections, Intradermal, Vaccination.
- prevention & control : Orthomyxoviridae Infections.
- virology : Lung.
- Animals, Disease Models, Animal, Immunity, Mucosal, Mice, Mice, Inbred BALB C, Survival Analysis, Viral Load.
Abstract
The emergence of the swine-origin 2009 influenza pandemic illustrates the need for improved vaccine production and delivery strategies. Skin-based immunization represents an attractive alternative to traditional hypodermic needle vaccination routes. Microneedles (MNs) can deliver vaccine to the epidermis and dermis, which are rich in antigen-presenting cells (APC) such as Langerhans cells and dermal dendritic cells. Previous studies using coated or dissolvable microneedles emphasized the use of inactivated influenza virus or virus-like particles as skin-based vaccines. However, most currently available influenza vaccines consist of solubilized viral protein antigens. Here we test the hypothesis that a recombinant subunit influenza vaccine can be delivered to the skin by coated microneedles and can induce protective immunity. We found that mice vaccinated via MN delivery with a stabilized recombinant trimeric soluble hemagglutinin (sHA) derived from A/Aichi/2/68 (H3) virus had significantly higher immune responses than did mice vaccinated with unmodified sHA. These mice were fully protected against a lethal challenge with influenza virus. Analysis of postchallenge lung titers showed that MN-immunized mice had completely cleared the virus from their lungs, in contrast to mice given the same vaccine by a standard subcutaneous route. In addition, we observed a higher ratio of antigen-specific Th1 cells in trimeric sHA-vaccinated mice and a greater mucosal antibody response. Our data therefore demonstrate the improved efficacy of a skin-based recombinant subunit influenza vaccine and emphasize the advantage of this route of vaccination for a protein subunit vaccine.
DOI: 10.1128/CVI.00435-10
PubMed: 21288996
Links to Exploration step
pubmed:21288996Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.</title><author><name sortKey="Weldon, William C" sort="Weldon, William C" uniqKey="Weldon W" first="William C" last="Weldon">William C. Weldon</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Martin, Maria P" sort="Martin, Maria P" uniqKey="Martin M" first="Maria P" last="Martin">Maria P. Martin</name></author><author><name sortKey="Zarnitsyn, Vladimir" sort="Zarnitsyn, Vladimir" uniqKey="Zarnitsyn V" first="Vladimir" last="Zarnitsyn">Vladimir Zarnitsyn</name></author><author><name sortKey="Wang, Baozhong" sort="Wang, Baozhong" uniqKey="Wang B" first="Baozhong" last="Wang">Baozhong Wang</name></author><author><name sortKey="Koutsonanos, Dimitrios" sort="Koutsonanos, Dimitrios" uniqKey="Koutsonanos D" first="Dimitrios" last="Koutsonanos">Dimitrios Koutsonanos</name></author><author><name sortKey="Skountzou, Ioanna" sort="Skountzou, Ioanna" uniqKey="Skountzou I" first="Ioanna" last="Skountzou">Ioanna Skountzou</name></author><author><name sortKey="Prausnitz, Mark R" sort="Prausnitz, Mark R" uniqKey="Prausnitz M" first="Mark R" last="Prausnitz">Mark R. Prausnitz</name></author><author><name sortKey="Compans, Richard W" sort="Compans, Richard W" uniqKey="Compans R" first="Richard W" last="Compans">Richard W. Compans</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21288996</idno><idno type="pmid">21288996</idno><idno type="doi">10.1128/CVI.00435-10</idno><idno type="wicri:Area/PubMed/Corpus">001119</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001119</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.</title><author><name sortKey="Weldon, William C" sort="Weldon, William C" uniqKey="Weldon W" first="William C" last="Weldon">William C. Weldon</name><affiliation><nlm:affiliation>Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Martin, Maria P" sort="Martin, Maria P" uniqKey="Martin M" first="Maria P" last="Martin">Maria P. Martin</name></author><author><name sortKey="Zarnitsyn, Vladimir" sort="Zarnitsyn, Vladimir" uniqKey="Zarnitsyn V" first="Vladimir" last="Zarnitsyn">Vladimir Zarnitsyn</name></author><author><name sortKey="Wang, Baozhong" sort="Wang, Baozhong" uniqKey="Wang B" first="Baozhong" last="Wang">Baozhong Wang</name></author><author><name sortKey="Koutsonanos, Dimitrios" sort="Koutsonanos, Dimitrios" uniqKey="Koutsonanos D" first="Dimitrios" last="Koutsonanos">Dimitrios Koutsonanos</name></author><author><name sortKey="Skountzou, Ioanna" sort="Skountzou, Ioanna" uniqKey="Skountzou I" first="Ioanna" last="Skountzou">Ioanna Skountzou</name></author><author><name sortKey="Prausnitz, Mark R" sort="Prausnitz, Mark R" uniqKey="Prausnitz M" first="Mark R" last="Prausnitz">Mark R. Prausnitz</name></author><author><name sortKey="Compans, Richard W" sort="Compans, Richard W" uniqKey="Compans R" first="Richard W" last="Compans">Richard W. Compans</name></author></analytic><series><title level="j">Clinical and vaccine immunology : CVI</title><idno type="eISSN">1556-679X</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Hemagglutinin Glycoproteins, Influenza Virus (administration & dosage)</term><term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term><term>Immunity, Mucosal</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Injections, Intradermal (methods)</term><term>Lung (virology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Orthomyxoviridae Infections (immunology)</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Survival Analysis</term><term>Th1 Cells (immunology)</term><term>Vaccination (methods)</term><term>Vaccines, Subunit (administration & dosage)</term><term>Vaccines, Subunit (immunology)</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (immunology)</term><term>Viral Load</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Influenza Vaccines</term><term>Vaccines, Subunit</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Influenza Vaccines</term><term>Vaccines, Subunit</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>Orthomyxoviridae Infections</term><term>Th1 Cells</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Injections, Intradermal</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Immunity, Mucosal</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Survival Analysis</term><term>Viral Load</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The emergence of the swine-origin 2009 influenza pandemic illustrates the need for improved vaccine production and delivery strategies. Skin-based immunization represents an attractive alternative to traditional hypodermic needle vaccination routes. Microneedles (MNs) can deliver vaccine to the epidermis and dermis, which are rich in antigen-presenting cells (APC) such as Langerhans cells and dermal dendritic cells. Previous studies using coated or dissolvable microneedles emphasized the use of inactivated influenza virus or virus-like particles as skin-based vaccines. However, most currently available influenza vaccines consist of solubilized viral protein antigens. Here we test the hypothesis that a recombinant subunit influenza vaccine can be delivered to the skin by coated microneedles and can induce protective immunity. We found that mice vaccinated via MN delivery with a stabilized recombinant trimeric soluble hemagglutinin (sHA) derived from A/Aichi/2/68 (H3) virus had significantly higher immune responses than did mice vaccinated with unmodified sHA. These mice were fully protected against a lethal challenge with influenza virus. Analysis of postchallenge lung titers showed that MN-immunized mice had completely cleared the virus from their lungs, in contrast to mice given the same vaccine by a standard subcutaneous route. In addition, we observed a higher ratio of antigen-specific Th1 cells in trimeric sHA-vaccinated mice and a greater mucosal antibody response. Our data therefore demonstrate the improved efficacy of a skin-based recombinant subunit influenza vaccine and emphasize the advantage of this route of vaccination for a protein subunit vaccine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21288996</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-679X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Clinical and vaccine immunology : CVI</Title><ISOAbbreviation>Clin. Vaccine Immunol.</ISOAbbreviation></Journal><ArticleTitle>Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.</ArticleTitle><Pagination><MedlinePgn>647-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/CVI.00435-10</ELocationID><Abstract><AbstractText>The emergence of the swine-origin 2009 influenza pandemic illustrates the need for improved vaccine production and delivery strategies. Skin-based immunization represents an attractive alternative to traditional hypodermic needle vaccination routes. Microneedles (MNs) can deliver vaccine to the epidermis and dermis, which are rich in antigen-presenting cells (APC) such as Langerhans cells and dermal dendritic cells. Previous studies using coated or dissolvable microneedles emphasized the use of inactivated influenza virus or virus-like particles as skin-based vaccines. However, most currently available influenza vaccines consist of solubilized viral protein antigens. Here we test the hypothesis that a recombinant subunit influenza vaccine can be delivered to the skin by coated microneedles and can induce protective immunity. We found that mice vaccinated via MN delivery with a stabilized recombinant trimeric soluble hemagglutinin (sHA) derived from A/Aichi/2/68 (H3) virus had significantly higher immune responses than did mice vaccinated with unmodified sHA. These mice were fully protected against a lethal challenge with influenza virus. Analysis of postchallenge lung titers showed that MN-immunized mice had completely cleared the virus from their lungs, in contrast to mice given the same vaccine by a standard subcutaneous route. In addition, we observed a higher ratio of antigen-specific Th1 cells in trimeric sHA-vaccinated mice and a greater mucosal antibody response. Our data therefore demonstrate the improved efficacy of a skin-based recombinant subunit influenza vaccine and emphasize the advantage of this route of vaccination for a protein subunit vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weldon</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Maria P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Zarnitsyn</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Baozhong</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Koutsonanos</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Skountzou</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Prausnitz</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Compans</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AI074579</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB006369</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB006369-03</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 EB012495</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB006369-01A1</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB006369-04</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB006369</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 EB012495-01</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB006369-02</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI074579</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Vaccine Immunol</MedlineTA><NlmUniqueID>101252125</NlmUniqueID><ISSNLinking>1556-679X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007271" MajorTopicYN="N">Injections, Intradermal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21288996</ArticleId><ArticleId IdType="pii">CVI.00435-10</ArticleId><ArticleId IdType="doi">10.1128/CVI.00435-10</ArticleId><ArticleId IdType="pmc">PMC3122571</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2010;5(5):e10645</Citation><ArticleIdList><ArticleId IdType="pubmed">20498717</ArticleId></ArticleIdList></Reference><Reference><Citation>J Invest Dermatol. 2010 May;130(5):1345-54</Citation><ArticleIdList><ArticleId IdType="pubmed">20107482</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Aug;84(15):7760-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20484519</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2010 Aug;16(8):915-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20639891</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010;5(9). pii: e12466. doi: 10.1371/journal.pone.0012466</Citation><ArticleIdList><ArticleId IdType="pubmed">20824188</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2000 May;74(10):4746-54</Citation><ArticleIdList><ArticleId IdType="pubmed">10775613</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2000 Jun;74(11):4999-5005</Citation><ArticleIdList><ArticleId IdType="pubmed">10799573</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 2002 Jan;19(1):63-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11837701</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2002 Aug 5;196(3):303-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12163559</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Feb 20;421(6925):852-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12594515</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2003 Jun 20;21(21-22):2830-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12798624</ArticleId></ArticleIdList></Reference><Reference><Citation>J Leukoc Biol. 2004 Feb;75(2):163-89</Citation><ArticleIdList><ArticleId IdType="pubmed">14525967</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Kidney Dis. 2004 May;43(5):910-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15112182</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2004 Aug 1;173(3):1978-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15265932</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hyg (Lond). 1972 Dec;70(4):767-77</Citation><ArticleIdList><ArticleId IdType="pubmed">4509641</ArticleId></ArticleIdList></Reference><Reference><Citation>J Invest Dermatol. 1983 Jun;80 Suppl:12s-16s</Citation><ArticleIdList><ArticleId IdType="pubmed">6602189</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 1999 Apr;37(4):937-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10074505</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Nov 25;351(22):2295-301</Citation><ArticleIdList><ArticleId IdType="pubmed">15525714</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunol. 1989 Sep;1(1):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15630959</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Apr 8;23(20):2565-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15780438</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunol. 2005 Aug;17(4):273-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15953735</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Jan 5;439(7072):38-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16397490</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Aug 28;24(35-36):6110-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16766095</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2007 Feb 12;117(2):227-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17169459</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2007 Apr;14(4):375-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17329444</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunopathol. 2007 Apr;29(1):15-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17621951</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2008 Apr 25;283(17):11382-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18252707</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Immunol. 2001 May;Chapter 19:Unit 19.11</Citation><ArticleIdList><ArticleId IdType="pubmed">18432752</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin J Pain. 2008 Sep;24(7):585-94</Citation><ArticleIdList><ArticleId IdType="pubmed">18716497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2008 Nov;26(11):1261-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18997767</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009;4(3):e4773</Citation><ArticleIdList><ArticleId IdType="pubmed">19274084</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2009 Apr;10(4):385-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19252490</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 May 18;27(23):3063-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19428920</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 May 12;106(19):7968-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19416832</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009;4(9):e7152</Citation><ArticleIdList><ArticleId IdType="pubmed">19779615</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2009 Oct;9(10):679-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19763149</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Nov 16;27(49):6932-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19761836</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Nov 27;27(51):7214-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19925956</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010;5(2):e9161</Citation><ArticleIdList><ArticleId IdType="pubmed">20161790</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2010 Jul 1;27(7):597-605</Citation><ArticleIdList><ArticleId IdType="pubmed">20583853</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001119 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001119 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21288996
|texte= Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21288996" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |